Zusammenfassung
Antipsychotika (früherer Begriff Neuroleptika) sind Neuro‑/Psychopharmaka, die vorrangig zur symptomatischen Behandlung von Erkrankungen aus dem schizophrenen Formenkreis eingesetzt werden sowie bei psychotischen Symptomen im Rahmen anderer Störungen (u. a. affektive oder organisch bedingte Störungen) und bei Manie. Einige werden in der Kinder- und Jugendpsychiatrie aber auch als Stimmungsstabilisatoren, bei Tic-Störungen und zudem symptomatisch bei Reizbarkeit, Agitiertheit und aggressiven Verhaltensweisen sowie Anspannung, Einschlafstörungen oder gedanklicher Einengung angewandt.
In diesem Kapitel werden die Klassifikation und Wirk(ungs)mechanismen der Antipsychotika, die in der Kinder- und Jugendpsychiatrie eingesetzt werden, besprochen und schwerpunktmäßig diejenigen pharmakologischen Aspekte von Antipsychotika dargestellt, die für klinisch tätige ärztliche Kollegen für den therapeutischen Einsatz dieser Substanzen relevant sind. Dabei wird u. a. auf Anwendungsgebiete, die klinische Wirksamkeit und die Studienlage eingegangen. Es werden Dosierungsempfehlungen gegeben und mögliche unerwünschte Arzneimittelwirkungen und -wechselwirkungen behandelt. Das Kapitel schließt mit Empfehlungen zur Behandlungsdauer sowie zu notwendigen Kontrolluntersuchungen im Rahmen der Pharmakotherapie mit Antipsychotika.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
AACAP Official Action (2001) Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Psy 40(Suppl):4–S23
Al-Dhaher Z, Kapoor S, Saito E et al. (2016) Activating and tranquilizing effects of first-time treatment with aripiprazole, olanzapine, quetiapine, and risperidone in youth. J Child Adolesc Psychopharmacology 26:458–470
Aman MG, Mcdougle CJ, Scahill L et al. (2009) Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. J Am Acad Child Psy 48:1143–1154 (for the Research Units on Pediatric Psychopharmacology Autism Network)
Amato D, Canneva F, Cumming P et al. (2020) A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. Mol Psychiatry 25:2101–2118
Amor LB (2012) Antipsychotics in pediatric and adolescent patients: a review of comparative safety data. J Affect Disorders 138:22–S30
Ayanthi AR, Hickman IJ, Wang AYH et al. (2006) Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum. J Clin Psychopharm 26:232–237
Bai YH, Liu TB, Xu AH, Yang HC, Gao KM (2019) Comparison of common side effects from mood stabilizers and antipsychotics between pediatric and adult patients with bipolar disorder: a systematic review of randomized, double-blind, placebo-controlled trials. Expert Opin Drug Safety 18:703–717
Baptista T, Kin Y, Beaulieu S, de Baptista EA (2002) Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35:205–219
Benes FM (2009) Neural circuitry models of schizophrenia: Is it dopamine, GABA, glutamate, or something else? Biol Psychiat 65:1003–1005
Bernagie C, Danckaerts M, Wampers M, De Hert M (2016) Aripiprazole and acute extrapyramidal symptoms in children and adolescents: a meta-analysis. CNS Drugs 30:807–818
Brannan SK, Sawchak S, Miller AC et al. (2021) Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. New Engl J Med 384:717–726
Brown AS (2011) The environment and susceptibility to schizophrenia. Prog Neurobiol 93:23–58
Calarge CA, Burns TL, Schlechte JA, Zemel BS (2015) Longitudinal examination of the scelettal effects of selective serotonin reuptake inhibitors an risperidone in boys. J Clin Psychiatry 76:607–613
Campbell M, Small AM, Green WH et al. (1984) A comparison of haloperidol and lithium in hospitalized aggressive conduct disordered children. Arch Gen Psychiat 41:650–656
Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140–144
Carpenter WT, Davis JM (2012) Perspective. Another view of the history of antipsychotic drug discovery and development. Mol Psychiatr 17:1168–1173
Ceraso A, Lin JJ, Schneider-Thoma J et al. (2020) Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 11:Cd8016
Chandradasa M, Ruwanpriya S, de Silva S, Rathnayake L, Kuruppuarachchi K (2022) Randomised, placebo-controlled trial on topiramate add-on therapy for weight reduction and symptomatology in overweight/obese persons with schizophrenia. Asian J Psychiatr 68:102963. https://doi.org/10.1016/j.ajp.2021.102963
Chang C-Y, Luo D-Z, Pei J-C et al. (2021) Not just a bystander: The emerging role of astrozytes and research tools in studying cognitive dysfunctions in schizophrenia. Int J Mol Sci 22:5343. https://doi.org/10.3390/ijms22105343
Cohen D, Huinink S (2007) Atypical antipsychotic-induced diabetes mellitus in child and adolescent psychiatry. CNS Drugs 21:1035–1038
Comai S, Tau M, Pavlovic Z, Gobbi G (2012) The psychopharmacology of aggressive behavior: a translational approach. Part 2: Clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J Clin Psychopharm 32:237–260
Correll CU (2008) Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Psy 47:9–20
Correll CU (2011) Antipsychotic agents: traditional and atypical. In: Martin A, Scahill L, Kratochvil (Hrsg) Pediatric psychopharmacology. Principles and practise, 2. Aufl. University Press, Oxford New York, S 312–337
Correll Ch, Carlson HE (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Psy 45:771–791
Correll CU, Kane JM (2007) One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol 17:647–655
Correll CU, Sheridan EM, DelBello MP (2010) Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 12:116–141
Correll CU, Kratochvil CJ, March JS (2011) Development in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiat 72:655–670
Correll CU, Kohegy E, Zhao C (2017) Oral aripiprazole as maintenance treatment in adolsescent schizophrenia: results from a 52-week, randomized, placebo-controlles withdrawal study. J Am Acad Child Adolesc Psychiatry 56:784–792
Correll CU, Litman RE, Filts Y et al. (2020a) Efficacy and safety of once monthly Risperidone ISM in schizophrenic patients with acute exacerbation. Schizophrenia 6:37
Correll CU, Sikich L, Reeves G et al. (2020b) Metformin add-on vs. Antipsychotic switch vs. Continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry 19:69–80
Coustals N, Ménard ML, Cohen D (2020) Aripiprazole in children and adolescents. J Child Adolesc Psychopharmacol 20:1–29
Creese I, Burt DR, Snyder SH (1976) Dopamine receptors binding predicts clinical potencies of antischizophrenic drugs. Science 192:481–483
DeNayer A, DeHert M, Scheen A, Van Gaal L, Peuskens J (2007) Belgian consensus on metabolic problems associated with atypical antipsychotics. Encephale 33:197–202
DelBello MP, Goldman R, Philips D et al. (2017) Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo controlled study. J Am Acad Child Adolesc Psychiatry 56:1015–1025
Dietmaier O, Laux G (2020) Weiterbildungs-Curriculum Pschopharmakologie/Pharmakotherapie. Teil 15: Kombinationstherapien, Interaktionen. Psychopharmakotherapie 27:295–305
Ebdrup BH, Knop FK (2021) Weight gain on antipsychotics - A perfect storm of complex pathophysiology and psychopharmacology. Acta Psychiatr Scand 144:521–523
Egberts K, Mehler-Wex C, Gerlach M (2011) Therapeutic drug monitoring in child and adolescent psychiatry. Pharmacopsychiatry 44:249–253
Eggers C, Roepcke B (2007) Schizophrenie, schizotype und wahnhafte Störungen (F2). In: Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie, Bundesarbeitsgemeinschaft Leitender Klinikärzte für Kinder- und Jugendpsychiatrie, Psychotherapie und Bundesverband der Ärzte für Kinder- und Jugendpsychiatrie und Psychotherapie (Hrsg) Leitlinien zu Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter, 3. Aufl. Deutscher Ärzte-Verlag, Köln, S 33–43
Eggers C, Rothenberger A, Berghaus U (1988) Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psy Clin N 237:223–229
Ellul P, Delorme R, Cortese S (2018) Metformin for weight gain associated with second generation antipsychotics in children and adolescents: a systematic review and meta-analysis. CNS Drugs 32:1103–1112
FDA (2016) FDA warns about rare but serious skin reactions with mental health drug olanzapine. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-rare-serious-skin-reactions-mental-health-drug (Erstellt: 10. Mai 2016)
Findling RK, Cavus I, Pappadopulos E et al.(2013) Ziprasidone in adolescents with schizophrenia: Results from a placebo-controlled efficacy and long-term open-extension study. J Child Adoles Psychopharmacol 23:531-544
Findling RL, Landbloom RP, Mackle M et al. (2015a) Safety and efficacy from an 8 week double-blind trial and a 26 week open label extension of asenapine in children and adolescents with schizophrenia. J Child Adolesc Psychopharmacol 25:384–396
Findling RL, Landbloom RL, Szegedi et al. (2015b) Asenapine for the acute treatment of pediatric manic or mixed episode of bipolar I disorder. J Am Acad Child Adolesc Psychiatry 54:1032–1041
Fleischhaker Ch, Heiser P, Hennighausen K et al. (2008) Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. J Neural Transm 115:1599–1608
Fountoulakis KN, Moeller HJ, Kasper S et al. (2021) The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. CNS Spectr 26:562–586
Fraguas D, Correll CU, Merchán-Naranjo J et al. (2011) Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharm 21:621–645
Friedrich ME, Winkler D, Konstantinidis A et al. (2020) Cardiovascular adverse reactions during antipsychotic treatment: results of AMSP, a drug surveillance program between 1993 and 2013. Int J Psychopharmacol 23:67–75
Galling B, Roldán A, Nielsen RE et al. (2016) Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry 73:247–259
Galling B, Roldán A, Hagi K et al. (2017) Antipsychotic augementation versus monotherapy in schiziphrenia: a systematic review, meta-analysis und meta-regression analysis. World Psychiatry 16:77–89
Gebicke-Haerter PJ (2012) Epigenetics of schizophrenia. Pharmacopsychiatry 45(Suppl 1):S42–S48
Gerlach M (2021) Pharmakologische und rechtliche Grundkenntnisse der Psychopharmakotherapie. Psych Up2date 15:71–84
Gerlach M, Hünnerkopf R, Rothenhöfer S et al. (2007) Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry 40:72–76
Giessing Jensen K, Juul K, Fink-Jensen A, Correll CU (2015) Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychaitry 54:25–36
Glassman AH, Bigger Th (2001) Antipsychotic drugs: Prolonged QTc interval, torsade de pointes and sudden death. Am J Psychiat 158:1774–1782
Goedhard LE, Stolker JJ, Herrdink ER et al. (2006) Pharmacotherapy of aggressive behavior in general adult psychiatry: A systematic review. J Clin Psychiat 67:1013–1024
Goldman R, Loebel A, Cucchiaro J (2017) Efficacy and safety of lurasidone in adolescents with schizophrenia: a six-week, randomized placebo controlled study. J Child Adolesc Psychopharmacol 27:516–525
Goldstein BI, Sassi R, Diler RS (2012) Pharmacological treatment of bipolar disorder in children and adolescents. Child Adolesc Psychiatr Clin N 21:911–939
Grohmann R, Hippius H, Rüther R (2001) Extrapyramidal motor side-effects and blood profile changes. Stumbling blocks in psychiatric pharmacotherapy. MMW Fortschr Med 77(Suppl 2):76–77
Guber KM, Cortes ND, Duan L (2021) Risk of obesity among children prescribes atypical antipsychotics for six months or more. J Child Adolesc Psychiatry. https://doi.org/10.1089/cap.2021.0021
Guinart D, Taipale H, Rubio JM et al. (2021) Risk Factors, incidence, and outcomes of neuroleptic malignant syndrome on long-acting injectable vs oral antipsychotics in a nationwide schizophrenia cohort. Schizophr Bull 476:1621–1623
Haase HJ (1954) About prevalence and interpretation of the psychomotor Parkinson syndrome in megaphen or largactil treatment duration. Nervenarzt 25:486–492
Haase HJ, Janssen PAJ (1965) The action of neuroleptic drugs. Year Book Medical, Chicago
Hasan A, Falkai P, Wobrock T et al. (2015) World Federation of Societis of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry 16:142–170 (on behalf of the WFSBP Task Force on Treatment Guidelines for Schizophrenia)
Häßler F, Dück A, Jung M, Reis O (2014) treatment of aggressive behavior problems in boys with intellectual disabilities using zuclopenthixol. J Child Adolesc Psychopharmacol 24:579–581
Heck J, Krichewsky B, Krause O et al. (2021) Photosensibilisierung durch Psychopharmaka und andere Arzneimittel. Psychopharmakotherapie 28:94–101
Henderson DC, Cagliero E, Copeland PM et al. (2007) Elevated hemoglobin A1c as possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atipycal antipsychotics. J Clin Psychiat 68:533–541
Hiemke C, Pfuhlmann B (2012) Interactions and monitoring of antipsychotic drugs. Handb Exp Pharmacol 212:241–265
Hiemke C, Bergemann N, Clement HW et al. (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology - Update 2017. Pharmacopsychiatry 51:9–62
Højlund M, Kemp AF, Haddad PM et al. (2021) Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Lancet Psychiatry 8:471–486
Howes O, McCutcheon R, Stone J (2015) Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol 29:97–115
Howes OD, McCutcheon R, Owen MJ, Murray RM (2017) The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry 81:9–20
Huber M, Schlosser-Weber G, Paeschke N, Broich K (2015) Antipsychotika in der Schwangerschaft. Psychopharmakotherapie 22:278–285
Huhn M, Nikolakopoulou A, Schneider-Thoma J et al. (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394:939–951
Huybrechts KF, Hernandez-Diaz S, Patorno E et al. (2016) Antipsychotic use in pregnancy and the risk of congenital malformations. JAMA Psychiatry 73:938–946
Jensen KG, Juul K, Fink-Jensen A, Correll CU, Pagsberg AK (2015) Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry 54:25–36
Kaar SJ, Natesan S, McCutcheon R, Howes OD (2020) Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2019.107704
Kapur S, Seeman P (2000) Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatr Neurosci 25:161–166
Kapur S, Seeman P (2001) Does fast dissociation from the dopamine D2 receptor explaine the action of atypical antipsychotics? A new hypothesis. Am J Psychiat 158:360–369
Keefe RSE, Bilder RM, Davis SM et al. (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiat 64:633–647 (CATIE investigators and the Neurocognitive Working Group)
Kegeles LS, Slifstein M, Frankle WG et al. (2008) Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology 33:3111–3125
Keks N, Hope J, Schwartz D et al. (2020) Comparative tolerability of dopamine D2/3 receptor partial agonists for schizophrenia. CNS Drugs 34:473–450
Kennedy WK, Jann MW, Kutscher EC (2013) Clinically significant drug interactions with atypical antipsychotics. CNS Drugs 27:1021–1048
Khandaker GM, Zimbron J, Dalman C, Lewis G, Jones PB (2012) Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophr Res 139:161–168
Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU (2019) Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-tohead comparisons. World Psychiatry 18:208–224
Klampfl K, Taurines R, Preuss A et al. (2010) Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. Pharmacopsychiatry 43:58–65
Koblan KS, Kent J, Hopkins SC et al. (2020) A non-D2-receptor-binding drug for the treatment of schizophrenia. New Engl J Med 382:1497–1506
Köster L-S, Carbon M, Correll CU (2014) Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs 19:511–531
Koller E, Schneider B, Bennett K, Dubitsky G (2001) Clozapine-associated diabetes. Am J Med 111:716–723
Koller EA, Cross JT, Schneider B (2004a) Risperidone-associated diabetis mellitus in children. Pediatrics 113:421–422
Koller EA, Weber J, Doraiswamy PM, Schneider BS (2004b) A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiat 65:857–863
Kornhuber J, Thome J, Riederer P (1998) Modellvorstellungen zur Ätiopathogenese der Schizphrenien. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuroleptika, 2. Aufl. Neuro-Psychopharmaka. Ein Therapie-Handbuch, Bd. 4. Springer, Wien, S 3–21
Koskuvi M, Lehtonen S, Trontti K et al. (2022) Contribution of astrocytes and clinical manifestation of schizophrenia. Glia 70:650–660
Kulkarni SK, Naidu PS (2003) Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drug Today 39:19–49
Labad J, Montalvo I, Gonzalez-Rodriguez A et al. (2020) Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinemia: a systematic review and meta-analysis. Schizophr Res 222:88–96
Laruelle M (2014) Schizophrenia: from dopaminergic to glutamatergic interventions. Curr Opin Pharmacol 14:97–102
Lee SE, Kronsberg H, Findling RL (2020) Psychopharmacologic treatment of schizophrenia in adolsecents and children. Child Adolesc Psychiatr Clin N Am 29:183–210
Lessig MC, Shapira NA, Murphy TK (2001) Topiramate reversing atypical antipsychotic weight gain. Letter J Am Acad Child Psy 40:1364
Leucht S, Corves C, Arbter D et al. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41
Li A, Zalesky A, Yue W et al. (2020) A neuroimaging biomarker for striatal dysfunction in schizophrenie. Nat Med 26:558-565
Libowitz MR, Nurmi EL (2021) The burden of antipsychotic-induced weight gain and metabolic syndrome in children. Front Psychiatry 12:623681 https://doi.org/10.3389/fpsyt.2021.623681
Lieberman JA (2004) Dopamine partial agonists. A new class of antipsychotics. CNS Drugs 18:251–267
Liu HY, Potter MP, Woodworth KY et al. (2011) Pharmcologic treatments for pediatric bipolar disorder: a review and meta-analysis. J Am Acad Child Psy 50:749–762
Loebel A, Brams M, Goldman R et al. (2016) Lurasidone for the treatment of irritability associated with autistic disorder. J Autism Dev Disord 46:1153–1163
López-Muñoz F, Alamo C, Cuenca E et al. (2005) History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry 17:113–135
Madaan V, Dvir Y, Wilson DR (2008) Child and adolescent schizophrenia: pharmacological approaches. Exp Opin Pharmacol 9:2053–2068
Man KKC, Shao SC, Chang YC et al. (2021) Cardiovascular and metabolic risk of antipsychotics in children and young adults: A multinational self-controlled case series study. Epidem Psychiatr Sci 30:e65. https://doi.org/10.1017/s2045796021000494
Marenco S, Weinberger DR (2000) The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev Psychopathol 12:501–527
Martin WF, Correll CU, Weiden PJ et al. (2019) Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. Am J Psychiatry 176:457–467
Masi G, Liboni F (2011) Management of schizophrenia in children and adolescents. Drugs 71:179–208
McCutcheon RA, Abi-Dargham A, Howes OD (2019) Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci 42:205–220
Mishara AL, Goldberg TE (2004) A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: Opening a closed book. Biol Psychiat 55:1013–1022
Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79–104
Möller HJ, Müller WE, Bandelow B (2001) Neuroleptika. Pharmakologische Grundlagen, klinisches Wissen und therapeutisches Vorgehen. Wissenschaftliche Verlagsgesellschaft, Stuttgart, S 243
Müller WE (2019) Vergleichende Betrachtung der pharmakologischen Eigenschaften von Dopamin-D2-Partialagonisten. Psychopharmakotherapie 26:192–204
Munawar N, Ahsan K, Muhammad K et al. (2021) Hidden role of gut microbiome dysbiosis in schizophrenia: antipsychotics or psychobiotics as therapeutics? Int J Mol Sci 22:7671. https://doi.org/10.3390/ijms22147671
Morrison JA, Cottingham EM, Barton BA (2002) Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiat 159:655–657
Naguy A, Adel T, Almazeedi I (2019) Paliperidone use in child psychiatry: evidence or diffidence? Pharmacology 104:67–70
Nevels RM, Dehon EE, Alexander K, Gontkovsky ST (2010) Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: A review of current and potentially promising treatment options. Exp Clin Psychopharm 18:184–201
Onishi Y, Mikami K, Kimoto K et al. (2021) Second-generation antipsychotic drugs for children and adolescents. Review. J Nippon Med Sch 88:10–16
Pagsberg AK, Tarp S, Glintborg D et al. (2017) Acute antipsychotic treatment with schizophrenia spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry 56:191–202
Patteet L, Morrens M, Maudens KE et al. (2012) Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit 34:629–651
Pillay J, Boylan K, Newton A et al. (2018) Harms of antipsychotics in children and adolescents: a systematic review update. Can J Psychiatry 63:661–678
Pozzi M, Ferrentino RI, Scrinzi C et al. (2020) Weight and body mass index increase in children and adolescents exposed to antipsychotic drugs in non-interventional settings: a meta-analysis and meta-regression. Eur J Child Adolesc Psychiatry. https://doi.org/10.1007/s00787-020-01582-9
Pringsheim T, Gorman D (2012) Second-generation antipsychotics for the treatment of disruptive behaviour disorders in children: a systematic review. Can J Psychiat 57:722–727
Pringsheim T, Lam D, Ching H, Patten S (2011) Metabolic and neurological complications of second-generation anti-psychotic use in children. Drug Saf 34:651–668
Rahman T, Sahrmann JM, Olsen MA et al. (2022) Risk of breast cancer with prolactin elevating antipsychotic drugs: an observational study of US women (Ages 18-64 years). J Clin Psychopharmacol 42:7–16
Razjouyan K, Danesh A, Khademi M, Davari-Ashtiani R, Noorbaksh S (2018) A comparative study of risperidone and aripiprazole in attention deficit hyperactivity disorder in children under six years old. A randomized double-blind study. Iran J Pediatr 28:e60087
Remington G, Hahn MK, Agarwal SM, Chintoh A (2021) Schizophrenia: Antipsychotics and drug development. Behav Brain Res 414:113507. https://doi.org/10.1016/j.bbr.2021.113507
Reyad AA, Mishriky R (2019) Asenapine: Pharmacological aspects and role in psychiatric disorders. Psychiatr Danube 31:157–161
Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M (2006) A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiat 163:402–410
Robb AS, Carson WH, Nyilas M et al. (2010) Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: Post-hoc analysis of randomized clinical trial data. J Child Adol Psychop 20:33–38
Sallee F, Kohegy E, Zhao J et al. (2017) Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole fort he treatment of Tourette’s disorder in children and adolescents. J Child Adolesc Psychopharmacol 27:771–781
Sallee FR, Kurlan R, Goetz CG et al. (2000) Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Psy 39:292–299
Scahill L, Lechman JF, Schultz RT, Katsovich L, Peterson BS (2003) A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130–1135
Schatzberg AF, Cole JO, De Battista C (2003) Manual of clinical psychopharmacology, 4. Aufl. American Psychiatric Publishing, Washington
Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU (2013) Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatr 26:219–230
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511:421–427
Seeman MV (2021) History of the dopamine hypetric Dothesis of antipsychotic action. World J Psychiatr 11:355–364
Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiat 47:27–38
Seeman P, Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217–1219
Seida JC, Schouten JR, Boylan K et al. (2012) Antipsychotics for children and youth adults: A comparative effectiveness review. Pediatrics 129:e771–e784
Shao P, Ou JJ, Peng M et al. (2015) Effects of clozapine and other atypical antipsychotics on infants development who were exposed to as fetus: a post-hoc analysis. Plos One 10:4 (Article Nr. e0123373)
Shapiro M, Reid A, Olsen B (2016) Topiramate and zonisamide and weight loss in children and adolscents prescribed psychiatric medications. Int J Psychiatry Med 51:56–68
Siafis S, Wu H, Wang DF et al. (2023) Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol Psychiatry. https://doi.org/10.1038/s41380-023-02203-y
Silva RR, Munoz DM, Alpert M, Perlmutter IR, Diaz J (1999) Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Psy 38:187–194
Singappuli P, Sonuga-Barke E, Kyriakopoulos M (2021) Antipsychotic long-term treatment in children und young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions. CNS Spectr. https://doi.org/10.1017/s1092852921000523
Singh J, Robb A, Vijapurkar U, Nuamah I, Hough D (2011) A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 70:1179–1188
Smith RC, Maayan L, Wu R et al. (2018) Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. Psychopharmacology 235:3545–3558
Solmi M, Pigato G, Kane JM, Correll CU (2018) Clinical risk factors for the development of tardive dyskinesia. J Neurol Sciences 389:21–27
Spencer EK, Kafantaris V, Padron-Gayol MV, Rosenberg CR (1992) Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull 28:183–186
Stentjeberg-Olesen M, Ganocy S, Findling R et al. (2015) Early response or non-response at week 2 and week 3 predict ultimate response or non-response in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. Eur Child Adolesc Psychiatry 24:1485–1496
Stigler KA, Potenza MN, Posey DJ, McDougle CJ (2004) Weight gain associated with atypical antipsychotic use in children and adolescents. Prevalence, clinical relevance, and management. Pediatr Drugs 6:33–44
Szatmari B, Barabassy A, Harsanyi J et al. (2020) Cariprazine safety in adolescents and the elderly: analysis of clinical study data. Front Psychiatry 11:61. https://doi.org/10.3389/fpsyt.2020.00061
S3-Leitlinie Schizophrenie (2019) https://www.awmf.org/uploads/tx_szleitlinien/038-009k_S3_Schizophrenie_2019-03.pdf
Tamminga CA (2006) Principles of pharmacology of schizophrenia. In: Charney DS, Nestler (Hrsg) Neurobiology of mental illnesses, 2. Aufl. Oxford University Press, Oxford, S 339–354
Tickell AM, Rohleder C, Ho NI et al. (2021) Identifying pathways to early-onset metabolic dysfunction, insulin resistance and inflammation in young adult inpatients with emerging affective and major mood disorders. Early Interv Psychiatry 16:1121–1129
Vancampfort D, Firth J, Correll CU et al. (2019) The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of Metaanalyses of randomized controlled trials. World Psychiatry 18:53–66
Vazquez-Bourgon J, Alario MI, Mayoral van Son J et al. (2020) A 3-year prospective study on the metabolic effect of aripiprazol, quetiapin and ziprasidone: a pragmatic clinical trial in first episode psychosis patients. Eur Neuropsychopharmacol 39:46–55
Vieta E, Montes E (2018) A review of asenapine in the treatment of bipolar disorder. Clin Drug Invest 38:87–99
Wagner E, Hasan A (2018) Cariprazin – eine neue medikamentöse Therapieoption in der Schizophreniebehandlung. Psychopharmakotherapie 25:278–285
Weizman S, Shelef A, Bris EB, Stryjer R (2021) A double-blind, placebo-controlled trial of bupropion add-on to olanzapine in overweight individuals with schizophrenia. J Clin Psychopharmacology 41:629-631
Wolkin A, Barouche F, Wolf A et al. (1989) Dopamine blockade and clinical response for two biological subgroups of schizophrenia. Am J Psychiatry 146:905–908
Wu QQ, Huang J, Wu RR (2021) Drugs based on NMDAR hypofunction hypothesis in schizophrenia. Front Neurosci 15:641047. https://doi.org/10.3389/fnins.2021.641047
Yee CS, Bahji A, Lolich M, Vazquez GH, Baldessarini RJ (2022) Comparative efficacy and tolerability of antipsychotics for juvenile psychotic disorders: a systematic review and network meta-analysis. J Clin Psychopharmacol 42:198–208
Zhao MJ, Qin B, Wang JB et al. (2018) Efficacy and acceptibility of cariprazine in acute exacerbation schizophrenia meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 38:55-59
Zuddas A, Zanni R, Usala T (2011) Second generation antipsychotics (SGas) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharm 21:600–620
Quellen und weiterführende Literatur
Fountoulakis KN, Moeller HJ, Kasper S et al. (2021) The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. CNS Spectr 26:562–586
Howes OD, McCutcheon R, Owen MJ, Murray RM (2017) The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry 81:9–20
Kaar SJ, Natesan S, McCutcheon R, Howes OD (2020) Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2019.107704
Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU (2013) Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatr 26:219–230
S3-Leitlinie Schizophrenie (2019) https://www.awmf.org/uploads/tx_szleitlinien/038-009k_S3_Schizophrenie_2019-03.pdf
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature
About this chapter
Cite this chapter
Mehler-Wex, C., Vloet, T.D., Gerlach, M. (2023). Antipsychotika. In: Gerlach, M., Mehler-Wex, C., Romanos, M., Walitza, S., Wewetzer, C. (eds) Neuro-/Psychopharmaka im Kindes- und Jugendalter. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-65267-1_6
Download citation
DOI: https://doi.org/10.1007/978-3-662-65267-1_6
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-65266-4
Online ISBN: 978-3-662-65267-1
eBook Packages: Psychology (German Language)